Recombinomics Presents Data and Analysis on Pandemic and Seasonal Influenza Evolution at Novel Vaccines Conference in Cambridge, Massachusetts

Aug 18, 2006, 01:00 ET from Recombinomics, Inc.

    PITTSBURGH, Aug. 18 /PRNewswire/ -- Analysis of recently released H5N1
 bird flu sequences from Indonesia and Hong Kong has revealed the geographic
 movement and recombination of H5N1 in Southeast Asia. Indonesia's Health
 Minister recently approved the release of over 400 human sequences dating
 back to July, 2005. Similarly, Hong Kong University released sequences from
 Hong Kong dating back to February 2006.
     This new data clearly indicates that H5N1 has been rapidly spreading
 and evolving via recombination. The sequences from Hong Kong were the
 Fujian strain, which has caused the recent reported human infections in
 China. That strain has now spread throughout Southeast Asia. The sequences
 from Indonesia indicated that all but one case outside of Karo have a novel
 cleavage site that does not match public poultry sequences. Moreover, the
 human sequences in Indonesia contain genetic sequences from both the Fujian
 and Qinghai strains, which are accelerating the evolution of the H5N1
 viruses. Recently, a new cluster in Garut Indonesia has been identified
     Recombinomics will be presenting analysis of these genetic changes at
 the Targeted Immunotherapeutics & Vaccine Summit in Cambridge,
 Massachusetts on Monday, August 21. Recombinomics President, Henry L,
 Niman, Ph.D. will present, "Pandemic and Seasonal Influenza Evolution Via
 Recombination - Selection of Vaccine Targets" at 9:35 AM and will be on a
 panel discussion on "Funding for Vaccines" at 4:30 PM.
     "The talk will include the important acquisition of new sequences by
 the various H5N1 strains in circulation as well as acquisitions by seasonal
 flu. The recently released sequences from Indonesia have significantly
 increased the influenza database available for analysis, which now provides
 some striking examples of H5N1's recombination driven evolution," said
 Henry Niman. He continued, "The newly released sequences demonstrate the
 utility of a robust sequence database for tracing the origins of influenza
 and selecting new vaccine targets for current vaccine production against
 future and emerging strains."
     Recombination is used by all rapidly evolving viruses, which creates a
 major challenge in vaccine development as well as the timing of vaccine
 production and distribution. Recombinomics has defined genetic acquisitions
 rules, which are applicable in the vaccine development process so that
 targets can be created prior to the emergence of new strains. The influenza
 sequence database is expanding rapidly, providing additional examples of
 various types of recombination, which can be exploited in the design of
 effective vaccines.
     Recombinomics, Inc. was founded by Dr. Henry Niman, a former Scripps
 Institute Assistant Member, based on his pioneering work in the area of
 viral evolution. Dr. Niman's research identified recombination as the
 underlying mechanism driving rapid genetic change, allowing him to file a
 series of patents based on a deep understanding of this paradigm shifting
 process. Recombinomics is in the process of commercializing its
 patent-pending approach to significantly improve the standard vaccine
 development process. Recombinomics, through its analysis and commentary
 section of its website (, has been
 consistently ahead of both the scientific community and government agencies
 in anticipating the genetic evolution and geographic expansion of H5N1.
     About The Targeted Immunotherapeutics & Vaccine Summit - Novel Vaccines
 show promise for protecting humanity from the scourge of disease, yet their
 worth is not always appreciated by the public, leading to shortfalls in
 funding and product. This summit features talks from leading innovators in
 the field of vaccines, ranging from cutting-edge research to breakthroughs
 in transporting and administering vaccines throughout the world. The
 conference is part of the Cambridge Healthtech Institute's conference
      Contact Information:     Dr. Henry Niman
                               Recombinomics, Inc.
                               Tel. 866.973.2662

SOURCE Recombinomics, Inc.